Technical Analysis for ADMA - ADMA Biologics Inc

Grade Last Price % Change Price Change
grade F 4.18 3.21% 0.13
ADMA closed down 6.47 percent on Thursday, November 14, 2019, on approximately normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical ADMA trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 3.21%
Below Lower BB Weakness 3.21%
Lower Bollinger Band Touch Weakness 3.21%
Oversold Stochastic Weakness 3.21%
Crossed Above 200 DMA Bullish -3.46%
Lower Bollinger Band Touch Weakness -3.46%
Oversold Stochastic Weakness -3.46%
Fell Below 200 DMA Bearish -0.24%
MACD Bearish Centerline Cross Bearish -0.24%
180 Bearish Setup Bearish Swing Setup -0.24%

Older signals for ADMA ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with high levels of naturally occurring polyclonal antibodies, as well as high levels of antibodies targeted to respiratory syncytial virus. The company also operates ADMA BioCenters, which are plasma collection centers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Medicine Biotechnology Biopharmaceutical Health Biology Pharmaceutical Industry Immunology Infectious Diseases Antibodies Immune System Antibody Glycoproteins Late Stage Biopharmaceutical
Is ADMA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 6.31
52 Week Low 2.08
Average Volume 795,653
200-Day Moving Average 4.2077
50-Day Moving Average 4.6639
20-Day Moving Average 4.686
10-Day Moving Average 4.603
Average True Range 0.3015
ADX 28.43
+DI 16.6904
-DI 23.54
Chandelier Exit (Long, 3 ATRs ) 4.3455
Chandelier Exit (Short, 3 ATRs ) 4.9245
Upper Bollinger Band 5.2943
Lower Bollinger Band 4.0777
Percent B (%b) -0.02
BandWidth 25.962441
MACD Line -0.0651
MACD Signal Line 0.0299
MACD Histogram -0.095
Fundamentals Value
Market Cap 104.46 Million
Num Shares 25.8 Million
EPS -1.77
Price-to-Earnings (P/E) Ratio -2.29
Price-to-Sales 5.85
Price-to-Book 2.60
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.55
Resistance 3 (R3) 4.59 4.47 4.46
Resistance 2 (R2) 4.47 4.34 4.45 4.43
Resistance 1 (R1) 4.26 4.27 4.20 4.22 4.41
Pivot Point 4.14 4.14 4.11 4.12 4.14
Support 1 (S1) 3.93 4.01 3.87 3.89 3.69
Support 2 (S2) 3.81 3.94 3.79 3.67
Support 3 (S3) 3.60 3.81 3.64
Support 4 (S4) 3.56